If
all goes as planned, Merck will soon take a major step forward in the
hot pursuit among pharmaceutical companies to produce a newer, better,
faster-working drug to treat the millions of people who have chronic
hepatitis C infection.
By midyear the company expects to submit a New Drug Application to the
Food and Drug Administration for approval of grazoprevir/elbasvir, a
combination regimen investigational drug designed to be taken once daily
as treatment of chronic hepatitis C virus infection. Grazoprevir is an
NS3/4A second-generation protease inhibitor and elbasvir is an NS5A
inhibitor.
- See more at:
http://www.hcplive.com/articles/Merck-to-Seek-Approval-of-New-Hepatitis-C-Drug-by-Midyear#sthash.maxgPR9Q.dpufLabels: grazoprevir/elbasvir (MK-5172/MK-8742), Merck